Genetic Chronic Obstructive Pulmonary Disease Market
According to Intent Market Research, the Genetic Chronic Obstructive Pulmonary Disease (COPD) Market is expected to grow from USD 5.4 billion in 2023 at a CAGR of 7.1% to touch USD 8.7 billion by 2030. The Genetic Chronic Obstructive Pulmonary Disease (COPD) Market is dominated by key players such as, Novartis International AG, GlaxoSmithKline (GSK), Pfizer Inc., Roche Holding AG, and Sanofi S.A.